Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
Boehringer Ingelheim
Harvard Business School
Medtronic

Last Updated: June 30, 2022

Sandoz Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for SANDOZ INC, and what generic alternatives to SANDOZ INC drugs are available?

SANDOZ INC has one hundred and forty-three approved drugs.

There are three US patents protecting SANDOZ INC drugs. There are seventeen tentative approvals on SANDOZ INC drugs.

There is one patent family member on SANDOZ INC drugs in one country and two hundred and fifty-eight supplementary protection certificates in sixteen countries.

Summary for Sandoz Inc

Drugs and US Patents for Sandoz Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc OXALIPLATIN oxaliplatin INJECTABLE;INTRAVENOUS 078812-001 Aug 7, 2009 DISCN No No See Plans and Pricing See Plans and Pricing
Sandoz Inc CEFTRIAXONE ceftriaxone sodium INJECTABLE;INJECTION 065204-002 May 3, 2005 AP RX No Yes See Plans and Pricing See Plans and Pricing
Sandoz Inc RASAGILINE MESYLATE rasagiline mesylate TABLET;ORAL 201892-002 Jul 27, 2018 AB RX No No See Plans and Pricing See Plans and Pricing
Sandoz Inc TOPOTECAN topotecan hydrochloride SOLUTION;INTRAVENOUS 200199-002 Feb 25, 2011 DISCN Yes No See Plans and Pricing See Plans and Pricing
Sandoz Inc PIPERACILLIN AND TAZOBACTAM piperacillin sodium; tazobactam sodium INJECTABLE;INJECTION 203557-001 Oct 29, 2014 AP RX No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sandoz Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sandoz Inc TIMOLOL MALEATE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020963-002 Oct 21, 1998 6,174,524*PED See Plans and Pricing
Sandoz Inc BETOPTIC betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 019270-001 Aug 30, 1985 4,311,708 See Plans and Pricing
Sandoz Inc ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873-001 Dec 15, 2000 5,196,404*PED See Plans and Pricing
Sandoz Inc TIMOLOL MALEATE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020963-001 Oct 21, 1998 6,174,524*PED See Plans and Pricing
Sandoz Inc BETOPTIC betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 019270-001 Aug 30, 1985 4,342,783 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SANDOZ INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Injection 250 mg/vial ➤ Subscribe 2009-09-01

Supplementary Protection Certificates for Sandoz Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1003503 SZ 30/2006 Austria See Plans and Pricing PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN
0300652 C300117 Netherlands See Plans and Pricing PRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830
1746976 LUC00026 Luxembourg See Plans and Pricing PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
0509752 C990041 Netherlands See Plans and Pricing PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0364417 SPC/GB97/014 United Kingdom See Plans and Pricing PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Mallinckrodt
Harvard Business School
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.